Atea Pharmaceuticals Inc (AVIR) - Total Assets
Based on the latest financial reports, Atea Pharmaceuticals Inc (AVIR) holds total assets worth $315.22 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See AVIR net asset value for net asset value and shareholders' equity analysis.
Atea Pharmaceuticals Inc - Total Assets Trend (2018–2025)
This chart illustrates how Atea Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. Check AVIR financial resilience to evaluate the company's liquid asset resilience ratio.
Atea Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Atea Pharmaceuticals Inc's total assets of $315.22 Million consist of 98.7% current assets and 1.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 30.4% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Atea Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Atea Pharmaceuticals Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Atea Pharmaceuticals Inc's current assets represent 98.7% of total assets in 2025, a decrease from 99.5% in 2018.
- Cash Position: Cash and equivalents constituted 30.4% of total assets in 2025, down from 98.9% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Atea Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Atea Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.82 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $146.48 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
|
Hyundai Bioscience Co. Ltd
KQ:048410
|
Korea | ₩130.74 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥772.57 Million |
|
Lifecome Biochemistry Co Ltd
SHE:002868
|
China | CN¥773.72 Million |
Atea Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.82 | 24.85 | 3.30 |
| Quick Ratio | 7.82 | 24.85 | 3.30 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $271.21 Million | $443.75 Million | $585.87 Million |
Atea Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Atea Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.58 |
| Latest Market Cap to Assets Ratio | 1.16 |
| Asset Growth Rate (YoY) | -32.2% |
| Total Assets | $315.22 Million |
| Market Capitalization | $364.12 Million USD |
Valuation Analysis
Above Book Valuation: The market values Atea Pharmaceuticals Inc's assets above their book value (1.16x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Atea Pharmaceuticals Inc's assets decreased by 32.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Atea Pharmaceuticals Inc (2018–2025)
The table below shows the annual total assets of Atea Pharmaceuticals Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $315.22 Million | -32.16% |
| 2024-12-31 | $464.67 Million | -21.90% |
| 2023-12-31 | $594.97 Million | -10.76% |
| 2022-12-31 | $666.71 Million | -13.74% |
| 2021-12-31 | $772.89 Million | -10.51% |
| 2020-12-31 | $863.63 Million | +3812.62% |
| 2019-12-31 | $22.07 Million | -36.68% |
| 2018-12-31 | $34.86 Million | -- |
About Atea Pharmaceuticals Inc
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company … Read more